Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Hospira, Inc.    HSP   US4410601003

HOSPIRA, INC. (HSP)

12
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Hospira : Applauds Delaware Governor’s Signing of Biosimilars Legislation

05/30/2014 | 12:42pm US/Eastern

LAKE FOREST, Ill., May 30, 2014 - Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today commended Delaware Gov. Jack Markell for his decision to sign Senate Substitute 1 for Senate Bill 118. This law creates a pathway for the substitution of interchangeable biologic drugs and helps pave the way for patient access to cost savings from biosimilar products.

When biosimilars become available in the United States in the coming years, clinicians will have opportunities to provide their patients with greater accessibility to effective and more affordable biologic drugs. The introduction of biosimilars could help the United States save up to $250 billion over 10 years, according to one report.

"The introduction of biosimilars promises to help put new cost-savings in the hands of patients and states, such as Delaware, that are taking early action to establish clear and transparent policies for the substitution of these high-quality and more affordable biologic products," said Paul Audhya, M.D., vice president, Medical Affairs, Hospira.

The governor's signature on Senate Substitute 1 for Senate Bill 118 allows pharmacists to substitute biosimilars for prescribed biological reference products unless the prescribing physician expressly requests the reference biologic.

Hospira is a market leader in biosimilars in Europe, and expects to submit its first biosimilar to the U.S. Food and Drug Administration (FDA) later this year or in early 2015.


distributed by
React to this article
Latest news on HOSPIRA, INC.
12:24p HOSPIRA : Inflectra™ (infliximab) patient registry reports interim results..
11:41a HOSPIRA : Statement on FDA Approval of the First Biosimilar in the United States
03/05 AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03/05 Biotech buys get pharma M&A off to flying start in 2015
03/05 AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03/04 BIOGEN IDEC : ISPE Carolina-South Atlantic Chapter Life Sciences Technology Conf..
02/27 HOSPIRA : Other Events (form 8-K)
02/25DJGeneric Copies of Remicade Go on Sale in Europe
02/25 Biosimilar copies of blockbuster drug launch in major EU markets
02/23 HOSPIRA : NYSE:HSP) Investor Alert: Lawsuit Against Takeover Filed
Advertisement
Chart
Duration : Period :
Hospira, Inc. Technical Analysis Chart | HSP | US4410601003 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF